Jakob Benedict Seidelin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8727401/publications.pdf

Version: 2024-02-01

81 papers	2,530 citations	218381 26 h-index	214527 47 g-index
83 all docs	83 docs citations	83 times ranked	4593 citing authors

#	Article	IF	Citations
1	Prediction of Relapse After Antiâ€“Tumor Necrosis Factor Cessation in Crohnâ€™s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 1671-1686.e16.	2.4	15
2	Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. Journal of Crohn's and Colitis, 2022, 16, 554-580.	0.6	43
3	Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases â€“ A Danish Prospective Population-Based Cohort Study with Individual-Level Data. Journal of Crohn's and Colitis, 2022, 16, 757-767.	0.6	13
4	Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis. Inflammatory Bowel Diseases, 2022, , .	0.9	5
5	Lipidomic Trajectories Characterize Delayed Mucosal Wound Healing in Quiescent Ulcerative Colitis and Identify Potential Novel Therapeutic Targets. International Journal of Biological Sciences, 2022, 18, 1813-1828.	2.6	5
6	Association Between the Clinical, Biochemical, and Endoscopic Activity of Inflammatory Bowel Diseases and Severity and Long-term Outcomes of Coronavirus Disease 2019â€”A Population-based Study. Inflammatory Bowel Diseases, 2022, , .	0.9	1
7	Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease â€“ a systematic review with meta-analysis. Digestive and Liver Disease, 2022, 54, 1168-1178.	0.4	17
8	Influence of Genetics, Immunity and the Microbiome on the Prognosis of Inflammatory Bowel Disease (IBD Prognosis Study): the protocol for a Copenhagen IBD Inception Cohort Study. BMJ Open, 2022, 12, e055779.	0.8	3
9	Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Diseaseâ€”A Danish Prospective Population-based Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 540-550.	0.6	63
10	Efficacy of ustekinumab for active perianal fistulizing Crohnâ€™s disease: a systematic review and meta-analysis of the current literature. Scandinavian Journal of Gastroenterology, 2021, 56, 53-58.	0.6	36
11	Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study. Inflammatory Bowel Diseases, 2021, 27, e37-e38.	0.9	10
12	Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?. Gut, 2021, 70, 2020-2022.	6.1	13
13	Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies â€“ A Danish population-based cohort study. Journal of Autoimmunity, 2021, 118, 102613.	3.0	41
14	CDX2 regulates interleukinâ€33 gene expression in intestinal epithelial cells (LS174T). FEBS Open Bio, 2021, 11, 1638-1644.	1.0	3
15	Effectiveness of Third-Class Biologic Treatment in Crohnâ€™s Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 2914.	1.0	8
16	Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohnâ€™s disease â€“ a real-world two-center cohort study. European Journal of Gastroenterology and Hepatology, 2021, 33, e709-e718.	0.8	11
17	Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scandinavian Journal of Gastroenterology, 2021, 56, 1040-1048.	0.6	12
18	IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine, 2021, 71, 103551.	2.7	16

#	Article	IF	Citations
19	Acute Experimental Barrier Injury Triggers Ulcerative Colitisâ€“Specific Innate Hyperresponsiveness and Ulcerative Colitisâ€“Type Microbiome Changes in Humans. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1281-1296.	2.3	7
20	Authorsâ€™ Reply to: â€˜COVID-19 in the IBD Population: The Need for Correct Nomenclatureâ€™. Journal of Crohn's and Colitis, 2021, 15, 1080-1080.	0.6	0
21	Crohnâ€™s Disease With Progressive Renal Impairment. Gastroenterology, 2020, 158, 58-59.	0.6	3
22	Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapyâ€”the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open, 2020, 10, e035756.	0.8	8
23	SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Science Signaling, 2020, 13, .	1.6	34
24	A fully defined 3D matrix for ex vivo expansion of human colonic organoids from biopsy tissue. Biomaterials, 2020, 262, 120248.	5.7	16
25	Fluorescence-based tracing of transplanted intestinal epithelial cells using confocal laser endomicroscopy. Stem Cell Research and Therapy, 2019, 10, 148.	2.4	11
26	Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies. Nature Communications, 2018, 9, 1661.	5.8	78
27	COX-2â€“PGE2 Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis. EBioMedicine, 2018, 36, 497-507.	2.7	63
28	Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterology, 2018, 5, e000208.	1.1	29
29	Asymptomatic Carriers Contribute to Nosocomial Clostridium difficile Infection: A Cohort Study of 4508 Patients. Gastroenterology, 2017, 152, 1031-1041.e2.	0.6	65
30	Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. EMBO Molecular Medicine, 2017, 9, 558-570.	3.3	69
31	Relation between NOD2 genotype and changes in innate signaling in Crohnâ€™s disease on mRNA and miRNA levels. Npj Genomic Medicine, 2017, 2, 3.	1.7	7
32	Objective Quantification of Immune Cell Infiltrates and Epidermal Proliferation in Psoriatic Skin: A Comparison of Digital Image Analysis and Manual Counting. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 453-458.	0.6	10
33	Will novel oral formulations change the management of inflammatory bowel disease?. Expert Opinion on Investigational Drugs, 2016, 25, 709-718.	1.9	23
34	Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. Journal of Gastroenterology, 2016, 51, 796-807.	2.3	11
35	Alpha-1 Antitrypsin and Granulocyte Colony-stimulating Factor as Serum Biomarkers of Disease Severity in Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 1077-1088.	0.9	17
36	GM6001 Increases Anastomotic Leakage following Colonic Obstruction Possibly by Impeding Epithelialization. Surgical Infections, 2015, 16, 702-708.	0.7	7

#	Article	IF	Citations
37	Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease. Clinical and Translational Gastroenterology, 2015, 6, e122.	1.3	17
38	IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. Journal of Gastroenterology, 2015, 50, 180-190.	2.3	61
39	Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. Clinical and Experimental Immunology, 2015, 179, 426-434.	1.1	18
40	Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation. American Journal of Physiology - Renal Physiology, 2015, 308, G92-G99.	1.6	18
41	ATG16L1: A multifunctional susceptibility factor in Crohn disease. Autophagy, 2015, 11, 585-594.	4.3	100
42	Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis. Scandinavian Journal of Gastroenterology, 2015, 50, 1-29.	0.6	33
43	Identification of TNF-Â-Responsive Promoters and Enhancers in the Intestinal Epithelial Cell Model Caco-2. DNA Research, 2014, 21, 569-583.	1.5	12
44	Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends in Molecular Medicine, 2014, 20, 652-665.	3.5	96
45	ERK controls epithelial cell death receptor signalling and cellular FLICE-like inhibitory protein (c-FLIP) in ulcerative colitis. Journal of Molecular Medicine, 2013, 91, 839-849.	1.7	20
46	Muramyl dipeptide responsive pathways in Crohnâ€™s disease: from NOD2 and beyond. Cellular and Molecular Life Sciences, 2013, 70, 3391-3404.	2.4	26
47	Mucosal Healing in Ulcerative Colitis. Advances in Clinical Chemistry, 2013, 59, 101-123.	1.8	25
48	Caspase 14 does not influence intestinal epithelial cell differentiation. Cell Death and Differentiation, 2013, 20, 524-524.	5.0	3
49	Tissue-regenerating functions of coagulation factorÂXIII. Journal of Thrombosis and Haemostasis, 2013, 11, 806-816.	1.9	28
50	miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World Journal of Gastroenterology, 2013, 19, 4289.	1.4	81
51	MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics. World Journal of Gastroenterology, 2012, 18, 4629.	1.4	88
52	Biological Treatment of Crohnâ€™s Disease. Digestive Diseases, 2012, 30, 121-133.	0.8	9
53	Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scandinavian Journal of Gastroenterology, 2012, 47, 518-527.	0.6	89
54	pcaGoPromoter - An R Package for Biological and Regulatory Interpretation of Principal Components in Genome-Wide Gene Expression Data. PLoS ONE, 2012, 7, e32394.	1.1	25

#	Article	IF	Citations
55	Non-IBD and Noninfectious Colitis. , 2012, , 493-499.		0
56	Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 395-404.	8.2	73
57	MAP kinases in inflammatory bowel disease. Clinica Chimica Acta, 2011, 412, 513-520.	0.5	138
58	Use of biological molecules in the treatment of inflammatory bowel disease. Journal of Internal Medicine, 2011, 270, 15-28.	2.7	34
59	A role for interleukin-33 in TH2-polarized intestinal inflammation?. Mucosal Immunology, 2011, 4, 496-502.	2.7	38
60	Involvement of cellular inhibitor of apoptosis protein 2 (cIAP2) in intestinal wound healing. FASEB Journal, 2011, 25, 121.1.	0.2	0
61	IL-33 is upregulated in colonocytes of ulcerative colitis. Immunology Letters, 2010, 128, 80-85.	1.1	139
62	Evidence for Impaired CARD15 Signalling in Crohn's Disease without Disease Linked Variants. PLoS ONE, 2009, 4, e7794.	1.1	17
63	Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflammatory Bowel Diseases, 2009, 15, 1032-1038.	0.9	103
64	Epithelial apoptosis: Cause or consequence of ulcerative colitis?. Scandinavian Journal of Gastroenterology, 2009, 44, 1429-1434.	0.6	26
65	Aeromedical Transport After Acute Myocardial Infarction. Journal of Travel Medicine, 2009, 16, 96-100.	1.4	8
66	W1568 Inhibitor of Apoptosis Protein-2 (cIAP2) Is Important for Colonic Epithelial Wound Healing. Gastroenterology, 2009, 136, A-693.	0.6	1
67	Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflammatory Bowel Diseases, 2008, 14, 1623-1629.	0.9	18
68	Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 1031-1038.	1.4	20
69	Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. Apmis, 2006, 114, 508-517.	0.9	26
70	Continuous cytokine exposure of colonic epithelial cells induces DNA damage. European Journal of Gastroenterology and Hepatology, 2005, 17, 363-369.	0.8	23
71	Insulin-like Growth Factor Binding Protein 3 in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2005, 50, 780-784.	1.1	7
72	Colonic epithelial cell turnover: possible implications for ulcerative colitis and cancer initiation. Scandinavian Journal of Gastroenterology, 2004, 39, 201-211.	0.6	14

#	Article	IF	Citations
73	Alcohol modulates circulating levels of interleukinâ€6 and monocyte chemoattractant proteinâ€1 in chronic pancreatitis. Scandinavian Journal of Gastroenterology, 2004, 39, 277-282.	0.6	16
74	Continuous interferon-? or tumor necrosis factor-? exposure of enterocytes attenuates cell death responses. Cytokine, 2004, 27, 113-119.	1.4	12
75	Expression of ICAM-1 in colon epithelial cells: an ultrastructural study performed on in vivo and in vitro models. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 774-781.	1.4	13
76	Simple and efficient method for isolation and cultivation of endoscopically obtained human colonocytes. American Journal of Physiology - Renal Physiology, 2003, 285, G1122-G1128.	1.6	29
77	Transcriptome changes during intestinal cell differentiation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1589, 160-167.	1.9	32
78	Soluble L-selectin levels predict survival in sepsis. Intensive Care Medicine, 2002, 28, 1613-1618.	3.9	52
79	Established and emerging biological activity markers of inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 359-367.	0.2	145
80	Circulating L-selectin levels and endothelial CD34 expression in inflammatory bowel disease. American Journal of Gastroenterology, 1998, 93, 1854-1859.	0.2	19
81	Seizure threshold to lidocaine is decreased following repeated ECS (electroconvulsive shock). Psychopharmacology, 1993, 111, 495-498.	1.5	5